When added to optimized RAS blockade and, ideally, SGLT2 inhibitor therapy, finerenone significantly lowers the risk of CKD progression and cardiovascular events, particularly heart failure hospitalizations [6]. This evidence concerns the gene SLC5A2 and heart failure.